Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists

Expert Rev Clin Immunol. 2019 Mar;15(3):211-213. doi: 10.1080/1744666X.2019.1559731. Epub 2018 Dec 27.

Authors

Sang T Kim¹, Maria E Suarez-Almazor¹

Affiliation

¹ a Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

PMID: 30589372
DOI: 10.1080/1744666X.2019.1559731

No abstract available

Keywords: Cancer immunotherapy; clinical practice guidelines; immune checkpoint inhibitors; immune-related adverse events; toxicity.

Publication types

Editorial

MeSH terms

Antineoplastic Agents, Immunological / adverse effects*
Humans
Immunotherapy / adverse effects*
Immunotherapy / methods
Neoplasms / drug therapy*
Practice Guidelines as Topic*

Substances

Antineoplastic Agents, Immunological